Bridging the gap: Why some people are not offered the medicines that NICE recommends


Nov 2012 by IMS Health
The extent of variation in the uptake of NICE recommended medicines across the NHS in England has been described before. The reasons for such variations are less well understood. IMS Health conducted a qualitative study during the summer and autumn of 2012 to help investigate the reasons for that variation. Eight therapy areas were discussed during interviews with experts, including hepatitis C (HCV). In this report a number of different factors are highlighted which together help to explain these variations in uptake. A number of recommendations are made which, if implemented, could make a positive difference to care across multiple therapy areas.